Phase I study to evaluate bioavailability of naproxen as PN400 compared to naproxen as Naprosyn E

Exclusion Criteria

• - Subject has received another investigational drug within 4 weeks preceding this study or planning to participate in another study at any time during the period of this study
• - Any significant medical or psychiatric condition that could affect the interpretation of the PK data, or which otherwise would contraindicate participation in a clinical trial
• - Any GI disease, abnormality or gastric surgery that may interfere with gastric emptying, motility and drug absorption
• - Subject who has donated a unit of blood or plasma within 3 months prior to the Screening Visit